2.26
-0.02(-0.88%)
Currency In USD
| Previous Close | 2.28 |
| Open | 2.27 |
| Day High | 2.27 |
| Day Low | 2.17 |
| 52-Week High | 9.19 |
| 52-Week Low | 1.61 |
| Volume | 205,504 |
| Average Volume | 184,482 |
| Market Cap | 21.52M |
| PE | -1.23 |
| EPS | -1.83 |
| Moving Average 50 Days | 1.95 |
| Moving Average 200 Days | 2.45 |
| Change | -0.02 |
If you invested $1000 in Daré Bioscience, Inc. (DARE) 10 years ago, it would be worth $5.1 as of December 17, 2025 at a share price of $2.26. Whereas If you bought $1000 worth of Daré Bioscience, Inc. (DARE) shares 5 years ago, it would be worth $166.67 as of December 17, 2025 at a share price of $2.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
GlobeNewswire Inc.
Dec 10, 2025 1:00 PM GMT
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal se
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced tha
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
GlobeNewswire Inc.
Nov 24, 2025 1:00 PM GMT
Grant funding will support continued progress on a preclinical research program to identify and develop a non-hormonal intravaginal contraceptive innovation aimed at addressing unmet global needsSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bi